Systematic review consolidates pharmacokinetics and pharmacodynamics of empagliflozin, aiding dose adjustments and minimizing adverse interactions.
that was 1.1-fold greater when administered alone but decreased in the presence of linagliptin. This systematic review consolidates all available PK and PD parameters of empagliflozin from accessible studies to assist clinicians in dose adjustment for patients with renal or hepatic impairment and type 2 diabetes, as well as in minimizing the risk of adverse reactions and drug-drug interactions.
No takes yet. Share an insight, caveat, or question.
Saleem et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: